Back to discover

Protein / target

Vesicular glutamate transporter 1

Encoded bySLC17A7Q9P2U7Homo sapiensSwiss-Prot
Antibody-tractable
Druggability
UniProt loc high conf
1
Research papers

Protein at a glance

Biological role

Glutamate-gated chloride channel

Strongest disease association

Parkinson's Disease

Via encoding gene SLC17A7 · Literature evidence · score 0.09

Research activity

Emerging research

1 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Multifunctional transporter that transports L-glutamate as well as multiple ions such as chloride, proton, potassium, sodium and phosphate.

View complete UniProt function annotation

Multifunctional transporter that transports L-glutamate as well as multiple ions such as chloride, proton, potassium, sodium and phosphate (PubMed:10820226). At the synaptic vesicle membrane, mainly functions as an uniporter which transports preferentially L-glutamate but also phosphate from the cytoplasm into synaptic vesicles at presynaptic nerve terminals of excitatory neural cells (By similarity). The L-glutamate or phosphate uniporter activity is electrogenic and is driven by the proton electrochemical gradient, mainly by the electrical gradient established by the vacuolar H(+)-ATPase across the synaptic vesicle membrane (By similarity). In addition, functions as a chloride channel that allows a chloride permeation through the synaptic vesicle membrane that affects the proton electrochemical gradient and promotes synaptic vesicles acidification (By similarity). Moreover, may function as a K(+)/H(+) antiport allowing to maintain the electrical gradient and to decrease chemical gradient and therefore sustain vesicular glutamate uptake (By similarity). The vesicular K(+)/H(+) antiport activity is electroneutral (By similarity). At the plasma membrane, following exocytosis, functions as a symporter of Na(+) and phosphate from the extracellular space to the cytoplasm allowing synaptic phosphate homeostasis regulation (PubMed:10820226). The symporter activity is driven by an inside negative membrane potential and is electrogenic (By similarity). Is necessary for synaptic signaling of visual-evoked responses from photoreceptors (By similarity)

Subcellular location

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCell membraneSynapse, synaptosome
Domains and Gene Ontology detail (30)

Gene Ontology

  • Ccerebellar mossy fiber
  • Cchloride channel complex
  • Cclathrin-sculpted glutamate transport vesicle membrane
  • Cexcitatory synapse
  • Cmembrane
  • Cplasma membrane
  • Cpostsynapse
  • Cpresynaptic active zone
  • Csynaptic vesicle membrane
  • Fchloride channel activity
  • Fextracellularly glutamate-gated chloride channel activity
  • FL-glutamate transmembrane transporter activity

560 aa · 62 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Chloride transportUniProt · GOExcitatory neurotransmissionGOIon channel gatingGO
View supporting evidence

Chloride transport

  • ·Multifunctional transporter that transports L-glutamate as well as multiple ions such as…
  • ·chloride channel complex
  • ·chloride channel activity
  • ·extracellularly glutamate-gated chloride channel activity

Excitatory neurotransmission

  • ·excitatory synapse
  • ·synaptic transmission, glutamatergic

Ion channel gating

  • ·phosphate ion transmembrane transport

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SLC17A7

Gene-level evidence surfaced through the gene SLC17A7that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic developmental and epileptic encephalopathy
0.26Preliminary

Animal model evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

Autistic Disorder
0.23Preliminary

Animal model evidence dominant · Open Targets 0.07 · no direct causal or clinical evidence

Undetermined early-onset epileptic encephalopathy
0.23Preliminary

Animal model evidence dominant · Open Targets 0.07 · no direct causal or clinical evidence

Glioblastoma
0.13Preliminary

RNA expression evidence dominant · Open Targets 0.06 · no direct causal or clinical evidence

Parkinson's Disease
0.11Preliminary

Literature evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

View evidence synthesis (5)
Genetic developmental and epileptic encephalopathyPreliminary
0.26
agreement 0.030.49
Animal model100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

Autistic DisorderPreliminary
0.23
agreement 0.050.41
Animal model93%Literature7%

Open Targets aggregate 0.07 · 2 independent evidence families · no direct causal or clinical evidence

Undetermined early-onset epileptic encephalopathyPreliminary
0.23
agreement 0.000.46
Animal model100%

Open Targets aggregate 0.07 · 1 independent evidence family · no direct causal or clinical evidence

GlioblastomaPreliminary
0.13
agreement 0.000.32
RNA expression53%Literature47%

Open Targets aggregate 0.06 · 2 independent evidence families · no direct causal or clinical evidence

Parkinson's DiseasePreliminary
0.11
agreement 0.000.38
Literature100%

Open Targets aggregate 0.09 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Parkinson's Disease0.09
Genetic developmental and epileptic encephalopathy0.08
Fragile X Syndrome0.07
Autistic Disorder0.07
Undetermined early-onset epileptic encephalopathy0.07
Alzheimer's Disease0.07
Glioblastoma0.06

Tractability

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
AB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.